Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy

BACKGROUND: Burosumab, a recombinant anti-FGF23 monoclonal antibody, was recently introduced as a treatment for X-linked hypophosphatemia (XLH). Burosumab normalizes blood phosphate levels, thereby healing rickets, decreasing leg bowing, and reducing pain. We aimed to explore the body composition an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ther Adv Endocrinol Metab
Hauptverfasser: Brener, Avivit, Lebenthal, Yael, Cleper, Roxana, Kapusta, Livia, Zeitlin, Leonid
Format: Artigo
Sprache:Inglês
Veröffentlicht: SAGE Publications 2021
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7970173/
https://ncbi.nlm.nih.gov/pubmed/33796255
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/20420188211001150
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge